Previous 10 | Next 10 |
Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food tech Pluristem and Tnuva are proven pioneers in cell culture technology and consumer food branding, with 100...
4 Penny Stocks to Watch as January Comes to an End As we come closer to the end of January, investors are hopeful that penny stocks can climb in 2022. But so far, the year has been highly volatile as many expected. Now, with the Omicron variant presenting a strange beacon of hope that C...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! I hope you enjoyed the long weekend, but it’s time to get back into investing with the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com New agreements, FDA ...
3 Penny Stocks to Watch in Mid-January 2022 With penny stocks and blue chips continuing to navigate the volatile waters of 2022, there is a lot for investors to understand. When it comes to penny stocks specifically, we see that speculation is extremely high. This means that knowing...
Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and development (R&D), consumer branding marketing, and sales and distr...
Gainers: PyroGenesis Canada (NASDAQ:PYR) +72%. Microbot Medical MBOT +50%. CollPlant Biotechnologies CLGN +32%. Future FinTech FTFT +41%. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. Spruce Biosciences (NASDAQ:SPRB) +31%. Tarena International TEDU +19%. CNF...
Gainers: Microbot Medical (NASDAQ:MBOT) +51%, CollPlant Biotechnologies (NASDAQ:CLGN) +27%, Lucira Health (NASDAQ:LHDX) +14%, IceCure Medical (NASDAQ:ICCM) +13%, Cue Health (NASDAQ:HLTH) +12%. Losers: BridgeBio Pharma (NASDAQ:BBIO) -71%, Biond...
Pluristem Therapeutics (NASDAQ:PSTI) falls 9.3% premarket after announcing topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLX-PAD cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) associ...
HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramus...
Having recruited patients in the U.S., Europe and Israel, t he Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event on m uscle r egeneration f...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...